What I enjoy about the negative views is that, founded in a bad past experience, they invariably lack any objective critical analysis about possibilities for the future. The past is nothing but a reference point for where we find ourselves now, and thus a steeping stone to the future.
The comment "dead-end technology" illustrates this perfectly. I doubt young Zed and his family think ReCell is a dead-end technology. Nor the surgeons who operated. Nor the thousands of other patients around the world whose lives have been transformed by ReCell. Nor the hundreds of KOLs and surgeons in multiple jurisdictions who now understand the benefits of ReCell are using it in ever-increasing numbers.
Clearly the USDOD does not see ReCell as a dead-end technology. Quite the opposite. They view ReCell as a "transformational technology which will redefine the clinical treatment of burns, scar remodelling, skin defects and other injuries," and have put millions of dollars on the table to back up their belief and help expedite the delivery of ReCell to the US healthcare market.
The only mistake is to not learn from your past mistakes. Even though they weren't his mistakes, Bill Dolphin knows this well. He has learned from his precessor's mistakes and is putting the lessons to good use. Patients and shareholders alike will be the beneficiaries of his expertise.
So from one who knew, time to move on. The future beckons for Avita, and it is rich with opportunity for those who can see it for what it is.
“For time and the world do not stand still. Change is the law of life. And those who look only to the past or the present are certain to miss the future.”
John F. Kennedy.
- Forums
- ASX - By Stock
- AVH
- from one who knew
from one who knew
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.82 |
Change
0.140(3.80%) |
Mkt cap ! $266.9M |
Open | High | Low | Value | Volume |
$3.83 | $3.87 | $3.77 | $1.433M | 374.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3987 | $3.82 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.86 | 200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3987 | 3.820 |
2 | 860 | 3.800 |
1 | 4 | 3.780 |
1 | 2000 | 3.770 |
1 | 7963 | 3.760 |
Price($) | Vol. | No. |
---|---|---|
3.860 | 200 | 1 |
3.870 | 9629 | 2 |
3.880 | 17056 | 3 |
3.890 | 6504 | 2 |
3.900 | 8380 | 3 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online